The randomized RELATIVITY-047 study which compared the co-formulation of anti-PD-1/anti-LAG-3 antibody, opdualag, versus anti-PD-1 treatment only in patients with untreated advanced melanoma, confirmed that abrogation of these two immune checkpoints is superior to nivolumab alone, with a PFS that is comparable to the combination treatment of anti-CTLA-4/anti-PD-1; although these two combinations have not been directly compared as yet in the same study [62]. The gene discussed is PDCD1; the disease is melanoma.